chromium picolinate
Jump to navigation
Jump to search
Introduction
Pharmaceutical form of
Indications
Dosage
Pharmacokinetics
Adverse effects
- potentially clastogenic[3] & cytotoxic[9]
- clinical reports of toxicity few & ambiguous[10]
- dermatitis[11]
Mechanism of action
- facilitates carbohydrate & lipid metabolism[2][5]
- reduces insulin resistance
- shortens QTc interval in overweight type 2 diabetics[1]
- no benefit in strength with resistance training[4]
- benefit for weight reduction may be small[7]
- tissue distribution[8]
- enters tissue cells intact
- taken up by kidney, muscle, & live
- subcellular location
- most in nucleus & mitochondria
- less in cytosol, lysosomes & microsomes
- see Cr+3
More general terms
Component of
- biotin/chromium picolinate
- chromium picolinate/inulin
- chromium/chromium picolinate/pyridoxine
- biotin/chromium/chromium picolinate
References
- ↑ Jump up to: 1.0 1.1 1.2 Vrtovec M, Vrtovec B, Briski A, Kocijancic A, Anderson RA, Radovancevic B. Chromium supplementation shortens QTc interval duration in patients with type 2 diabetes mellitus. Am Heart J. 2005 Apr;149(4):632-6. PMID: https://www.ncbi.nlm.nih.gov/pubmed/15990745
- ↑ Jump up to: 2.0 2.1 McCarty MF. Chromium picolinate may favorably influence the vascular risk associated with smoking by combating cortisol-induced insulin resistance. Med Hypotheses. 2005;64(6):1220-4. PMID: https://www.ncbi.nlm.nih.gov/pubmed/15823722
- ↑ Jump up to: 3.0 3.1 Yang X, Palanichamy K, Ontko AC, Rao MN, Fang CX, Ren J, Sreejayan N. A newly synthetic chromium complex--chromium(phenylalanine)3 improves insulin responsiveness and reduces whole body glucose tolerance. FEBS Lett. 2005 Feb 28;579(6):1458-64. PMID: https://www.ncbi.nlm.nih.gov/pubmed/15733857
- ↑ Jump up to: 4.0 4.1 Campbell WW, Joseph LJ, Ostlund RE Jr, Anderson RA, Farrell PA, Evans WJ. Resistive training and chromium picolinate: effects on inositols and liver and kidney functions in older adults. Int J Sport Nutr Exerc Metab. 2004 Aug;14(4):430-42. PMID: https://www.ncbi.nlm.nih.gov/pubmed/15467101
- ↑ Jump up to: 5.0 5.1 5.2 Rabinovitz H, Friedensohn A, Leibovitz A, Gabay G, Rocas C, Habot B. Effect of chromium supplementation on blood glucose and lipid levels in type 2 diabetes mellitus elderly patients. Int J Vitam Nutr Res. 2004 May;74(3):178-82. PMID: https://www.ncbi.nlm.nih.gov/pubmed/15296075
- ↑ Jump up to: 6.0 6.1 Kalman DS. Chromium picolinate and type 2 diabetes. Am J Clin Nutr. 2003 Jul;78(1):192; author reply 192-3. PMID: https://www.ncbi.nlm.nih.gov/pubmed/12816793
- ↑ Jump up to: 7.0 7.1 Pittler MH, Stevinson C, Ernst E. Chromium picolinate for reducing body weight: meta-analysis of randomized trials. Int J Obes Relat Metab Disord. 2003 Apr;27(4):522-9. PMID: https://www.ncbi.nlm.nih.gov/pubmed/12664086
- ↑ Jump up to: 8.0 8.1 8.2 Hepburn DD, Vincent JB. Tissue and subcellular distribution of chromium picolinate with time after entering the bloodstream. J Inorg Biochem. 2003 Feb 1;94(1-2):86-93. PMID: https://www.ncbi.nlm.nih.gov/pubmed/12620677
- ↑ Jump up to: 9.0 9.1 Manygoats KR, Yazzie M, Stearns DM. Ultrastructural damage in chromium picolinate-treated cells: a TEM study. Transmission electron microscopy. J Biol Inorg Chem. 2002 Sep;7(7-8):791-8. Epub 2002 Mar 23. PMID: https://www.ncbi.nlm.nih.gov/pubmed/12203015
- ↑ Jump up to: 10.0 10.1 Lamson DS, Plaza SM. The safety and efficacy of high-dose chromium. Altern Med Rev. 2002 Jun;7(3):218-35. Review. PMID: https://www.ncbi.nlm.nih.gov/pubmed/12126463
- ↑ Jump up to: 11.0 11.1 Fowler JF Jr. Systemic contact dermatitis caused by oral chromium picolinate. Cutis. 2000 Feb;65(2):116. PMID: https://www.ncbi.nlm.nih.gov/pubmed/10696566